All issues
Volume 45, Issue 12
Displaying 1-21 of 21 articles from this issue
- |<
- <
- 1
- >
- >|
-
Article type: Cover
1996 Volume 45 Issue 12 Pages Cover10-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (327K) -
Article type: Cover
1996 Volume 45 Issue 12 Pages Cover11-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (327K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1-20
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (1220K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 21-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (51K) -
Masaharu Muranaka, Hayao Ueno, Koichi Hirai, Kazunori Nakajima, Fusako ...Article type: Article
1996 Volume 45 Issue 12 Pages 1219-1230
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (1193K) -
Nobuya Ikuta, Hiroyuki Tangiguchi, Yasuhiro Kondoh, Kunihiko Gotoh, Ki ...Article type: Article
1996 Volume 45 Issue 12 Pages 1231-1236
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSWe studied retrospectively the effect of long-term treatment with an inhaled corticosteroid on bronchial hyperresponsiveness (BHR) and clinical asthma in moderate-severe asthmatic subjects. Fifty-eight patients who had used beclomethasone dipropionate (BDP) over one year, were enrolled in this study. BHR was measured before and after treatment with BDP by the methods recommended by Japanese Socitey of Allergology. Moreover we examined the clinical factors and the frequency of acute exacerbations. The results as follows: 1) The mean age was 48.8 years and the mean asthma history was 9.2 years. The mean dose and mean time of BDP administration was 801 μg/day and 28.1 months, respectively. 2) Patients during BDP treatment over one year showed about 6-fold mean improvements in BHR, but there were many patients who showed no improvements in BHR. 3) We retrospectively divided all the patients into two groups. Namely, the improved group (n = 25) showed more than 4 fold improvement in BHR and unchanged group (n = 33), less than 4-fold. But there were no significant differences in clinical characteristics and %FEV_1 during treatment with BDP. 4) The unchanged group had more near fatal episodes in the past than the improved group. 5) There was significant decrease in acute exacerbation during treatment with BDP, but the unchanged group had more acute exacerbations than the improved group during treatment with BDP. These results indicates that there are many patients who had no improvement on BHR with long term BDP treatment and they have more acute exacerbations due to various stimuli. In conclusion, asthma is recognized chronic inflammatory disease and inhaled corticosteroid therapy has been recommended as the first line therapy. We must further study the clinical problems and underlying mechanisms concerning about treatment with an inhaled corticosteroid.View full abstractDownload PDF (630K) -
Shumpei Yokota, Yuriko Takahashi, Yukoh Aihara, Kazuyuki Kurihara, Hir ...Article type: Article
1996 Volume 45 Issue 12 Pages 1237-1243
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSTo determine the allergenic proteins in commercially available butter and margarine, protein fractions were extracted and immunologically analyzed against milk, hen egg, and soybean antigens. Butter and 10 kinds of margarine were proved to contain these proteins in various concentrations by ELISA and immunoblotting methods by use of the rabbit antisera developed against each food proteins. However, hypoallergenic margarine was found to contain no such proteins at all. Using sera obtained from atopic dermatitis patients, previously detected high levels of IgE antibodies to milk, hen egg, or soybeans, the extracted protein fraction from butter and margarine was analyzed whether these proteins react with IgG antibodies in patients' sera. The sera with high levels of specific IgE recognized protein antigens in these extracts except those from hypoallergenic margarine, suggesting that proteins in butter and margarine may become allergenic for the patients sensitive to the proteins, and that hypoallergenic margarine will be a reasonable alternative for the allergic patients to milk, hen egg, or soybeans.View full abstractDownload PDF (905K) -
Yuriko TakahashiArticle type: Article
1996 Volume 45 Issue 12 Pages 1244-1255
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSHypersensitivity resulting from the ingestion or inhalation of buckwheat allergen causes immediate manifestation of symptoms including urticaria, wheezing, dyspnea, anaphylactic shock, which is consid-ered to be IgE-mediated type I hypersensitivity. Using sera of patients with buckwheat allergy the immuno-reactivity to purified buckwheat protein was investigated by enzyme-linked immunosorbent assay (ELISA) and immunoblotting method. The incidence of positive RAST value to buckwheat was 80% in the patients and 66.6% in the RAST-positive controls, whereas the RAST-negative controls showed all negative. The sera of both patients and RAST-positive controls showed significantly higher levels of specific IgG antibodies against salt-soluble and salt-insoluble fractions of buckwheat protein than the RAST-negative controls. By means of IgG-immunoblotting analysis, ten polypeptide bands of salt-soluble fraction and six polypeptides bands of salt-insoluble fraction were detected in all sera of the patients. In contrast, the patterns of IgE-immunoblots varied depending on the sera used. Taken together, the immune activation to buckwheat protein in patients with buckwheat allergy is not restricted to IgE antibody formation but extends to other immunoglobulin class, IgG, which indicating that the overall immune activation to buckwheat protein may be the basic characteristics of buckwheat allergy. Addition-ally, other factor is necessary for the manifestation of symptoms.View full abstractDownload PDF (1727K) -
Risa Nakahara, Shuhei Takemura, Hideki Onodera, Yoshihiro Kasamatsu, N ...Article type: Article
1996 Volume 45 Issue 12 Pages 1256-1261
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSThe effect of M-CSF and C5a on the expression of complement-related membrane proteins on the peripheral white blood cells was investigated. M-CSF or C5a was added into the suspension of the peripheral white blood cells. The expression of the complement receptors, CD35 (CR1) and CD11b/18 (CR3), and inhibitory membrane proteins, DAF and MCP, was measured by flow cytometry. M-CSF increased CR3 on polymorphonuclear cells (PMNs) and CR1, CR3, MCP and DAF on monocytes. C5a increased CR1, CR3 and DAF on PMNs, but did not affect the expression of those on monocytes. It is concluded that M-CSF possessed the activity of increase expression of both complement regulatory proteins and complement receptors of monocytes and C5a selectively affected the expression of those on PMNs.View full abstractDownload PDF (574K) -
Morio Sudo, Hitoshi Kobayashi, Tsugio Nakagawa, Junzaburo Kabe, Tadash ...Article type: Article
1996 Volume 45 Issue 12 Pages 1262-1269
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSThis study compares the characteristics of fatal asthma patients and those of near-fatal asthma patients who had experienced severe life threatening attacks. Data from 67 fatal asthma patients and 80 near-fatal asthma patients were analyzed. The mean age of fatal asthma cases were older than near-fatal asthma cases, 51.9 yrs and 44.3 yrs, respectively. Similarities of the two cases were seen in sex, type of asthma and severity of asthma. The experiences of previous life-thretening asthma did not differ in both groups (43.3% of fatal vs 40.0% of near-fatal). From the viewpoint of type of development of severe exacerbation, rapid exacerbation was more frequent in fatal cases than near-fatal cases, but acute exacerbation after unstable asthma was more in near-fatal asthma. Seventy-six percent of all asthma deaths occured at home or on the way to the emergency department. The rate of delay of receiving medical care was significantly higher in fatal cases (72%) than near-fatal cases (26%). There was no significant difference in the frequency of medical management before fatal or near-fatal episode such as oxygen therapy, mechanical ventilation. Use of ambullance, visiting emergency department, previous hospitalization between the two groups. The profile of fatal cases was almost same to that of near-fatal cases except delay of receiving medical care. In conclusion, the analysis of near-fatal cases was very important to make clear the causes of asthma death.View full abstractDownload PDF (882K) -
Yuichi Takahashi, Shigeto Kawashima, Shogo AikawaArticle type: Article
1996 Volume 45 Issue 12 Pages 1270-1276
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSThe effects of global warming on Japanese cedar pollen concentration in air were examined. There was a significant increase in total pollen count in years where small or average values of pollen dispersion were observed and where summertime temperatures were postulated to have risen from 2 to 5℃. There were no remarkable differences in total pollen count in years where large values of pollen dispersion were observed. On the other hand, a drastic decrease in total pollen count was expected when summertime temperatures were postulated to have dropped from 2 to 5℃. A major factor controlled the value of total pollen count was examined by use of a simulation method of airborne Cryptomeria japonica pollen. The values of total pollen count mainly controlled by the amount of male flower at basins and in Japanese cedar forested areas, and the manner in which plains isolated from pollen sources are considered in part to be subjected to meteorological conditions. The difference of initiation time of the pollen season has no great influence on the values of total pollen count.View full abstractDownload PDF (783K) -
Yukiko Ito, Yukimitsu Takahashi, Toru Matsuura, Masayoshi KobayashiArticle type: Article
1996 Volume 45 Issue 12 Pages 1277-1284
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSWe investigated when nasal symptoms in 219 patients with cedar pollinosis terminated in 1995. To study factors participating in symptom termination, we examined the rate of positive CAP RAST for antigens other than Japanese cedar in 121 patients, as well as nasal hypersensitivity to histamine and the number of basophilic cells or eosinophils in the surface layer of nasal mucosa in 53 patients before, during and after the Japanese cedar-cypress season. There were peak periods for the termination of nasal symptoms between the end of April and early May. Seventy percent of the patients had symptoms not only during the Japanese cedar season but also during the Japanese cypress season, and 23% of the patients had symptoms that persisted after the Japanese cypress season ended. In the group of patients with persistent symptoms after May (late group), the rate of positive CAP RAST for tree pollens other than Japanese cedar or cypress was higher than that in the early group of patients. Moreover in the late group, nasal hypersensitivity to histamine after the season ended remained significantly higher than that in the early group of patients. However, the number of basophilic cells or eosinophils after the season ended showed no significant difference between the early and late groups. In conclusion, sensitization for tree pollens other than Japanese cedar or cypress and nasal hypersensitivity after the season were important factors participating in the termination of nasal symptoms.View full abstractDownload PDF (737K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1285-1289
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (297K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1290-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (55K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1291-1292
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (108K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1293-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (79K) -
Article type: Index
1996 Volume 45 Issue 12 Pages 1294-1301
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (521K) -
Article type: Index
1996 Volume 45 Issue 12 Pages 1302-1304
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (123K) -
Article type: Index
1996 Volume 45 Issue 12 Pages 1305-1308
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (202K) -
Article type: Appendix
1996 Volume 45 Issue 12 Pages 1309-1315
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (561K) -
Article type: Cover
1996 Volume 45 Issue 12 Pages Cover12-
Published: December 30, 1996
Released on J-STAGE: February 10, 2017
JOURNAL FREE ACCESSDownload PDF (121K)
- |<
- <
- 1
- >
- >|